CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia

被引：17

作者：

Talati, Chetasi ^{[1
,2
]}

Lancet, Jeffrey E. ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL 33612 USA

[2] Univ S Florida, Dept Med, Tampa, FL 33612 USA

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 12期

关键词：

acute myeloid leukemia; CPX-351; induction chemotherapy; older adults with AML; secondary AML; therapy-related AML; OLDER PATIENTS; LIPOSOME INJECTION; MOLAR RATIO; AML; DAUNORUBICIN; CYTARABINEDAUNORUBICIN; CYTARABINE; ADULTS; CYTARABINE/DAUNORUBICIN; PHARMACOKINETICS;

D O I：

10.2217/fon-2017-0603

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple novel therapeutic agents against acute myeloid leukemia (AML) have been evaluated in the past several decades without meaningful clinical improvement in outcomes, especially for AML patients age 60, where the overall incidence of AML is highest. Therapeutic options mainly consist of hypomethylating agents, ongoing clinical trials and, less commonly, intensive cytotoxic chemotherapy. CPX-351, a novel liposomal formulation which encapsulates cytarabine and daunorubicin in 5:1 molar ratio, has shown promising efficacy, leading to recent US FDA approval for front-line therapy for patients with therapy-related AML and AML with myelodysplasia-related changes based on a large multicenter Phase III clinical trial. This review summarizes the clinical development of CPX-351 as induction therapy.

引用

页码：1147 / 1154

页数：8

共 22 条

[1]

[Anonymous], SURV EP END RESEER

[2]

[Anonymous], BLOOD

[3] Pharmacokinetics of CPX-351 (Cytarabine/Daunorubicin HCl) Liposome Injection in the Mouse [J].

Bayne, William F. ;

Mayer, Lawrence D. ;

Swenson, Christine E. .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (07) :2540-2548

[4]

BISHOP JF, 1990, BLOOD, V75, P27

[5] Phase II, Multicenter, Randomized Trial of CPX-351 (cytarabine: daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adults With First Relapse AML [J].

Cortes, Jorge E. ;

Goldberg, Stuart L. ;

Feldman, Eric J. ;

Rizzeri, David A. ;

Hogge, Donna E. ;

Larson, Melissa ;

Pigneux, Arnaud ;

Recher, Christian ;

Schiller, Gary ;

Warzocha, Krzysztof ;

Kantarjian, Hagop ;

Louie, Arthur C. ;

Kolitz, Jonathan E. .

CANCER, 2015, 121 (02) :234-242

[6] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].

Doehner, Hartmut ;

Estey, Elihu ;

Grimwade, David ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Larson, Richard A. ;

Levine, Ross L. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel ;

Sierra, Jorge ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wei, Andrew H. ;

Lowenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2017, 129 (04) :424-447

[7] International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts [J].

Dombret, Herve ;

Seymour, John F. ;

Butrym, Aleksandra ;

Wierzbowska, Agnieszka ;

Selleslag, Dominik ;

Jang, Jun Ho ;

Kumar, Rajat ;

Cavenagh, James ;

Schuh, Andre C. ;

Candoni, Anna ;

Recher, Christian ;

Sandhu, Irwindeep ;

Bernal del Castillo, Teresa ;

Al-Ali, Haifa Kathrin ;

Martinelli, Giovanni ;

Falantes, Jose ;

Noppeney, Richard ;

Stone, Richard M. ;

Minden, Mark D. ;

McIntyre, Heidi ;

Songer, Steve ;

Lucy, Lela M. ;

Beach, C. L. ;

Doehner, Hartmut .

BLOOD, 2015, 126 (03) :291-299

[8] Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia [J].

Feldman, E. J. ;

Kolitz, J. E. ;

Trang, J. M. ;

Liboiron, B. D. ;

Swenson, C. E. ;

Chiarella, M. T. ;

Mayer, L. D. ;

Louie, A. C. ;

Lancet, J. E. .

LEUKEMIA RESEARCH, 2012, 36 (10) :1283-1289

[9] First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia [J].

Feldman, Eric J. ;

Lancet, Jeffrey E. ;

Kolitz, Jonathan E. ;

Ritchie, Ellen K. ;

Roboz, Gail J. ;

List, Alan F. ;

Allen, Steven L. ;

Asatiani, Ekatherine ;

Mayer, Lawrence D. ;

Swenson, Christine ;

Louie, Arthur C. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) :979-985

[10] Anthracycline Dose Intensification in Acute Myeloid Leukemia [J].

Fernandez, Hugo F. ;

Sun, Zhuoxin ;

Yao, Xiaopan ;

Litzow, Mark R. ;

Luger, Selina M. ;

Paietta, Elisabeth M. ;

Racevskis, Janis ;

Dewald, Gordon W. ;

Ketterling, Rhett P. ;

Bennett, John M. ;

Rowe, Jacob M. ;

Lazarus, Hillard M. ;

Tallman, Martin S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13) :1249-1259

← 1 2 3 →